Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin for Prevention of Early Allograft Dysfunction in Liver Transplantation
NCT03031470Phase 2Terminated
- Sponsor
- Dompé
- Start
- Mar 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of reparixin in Early allograft dysfunction (EAD) (2 arms), sponsored by Dompé. Primary endpoint: Incidence of Early Allograft Dysfunction Within 7 Days After OLT. Started Mar 2015; status: terminated.
02
Drugs
reparixin
03
Conditions
Early allograft dysfunction (EAD)
Beyond the preview
Go deeper on NCT03031470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031470.